Scottish Medicines Consortium



Risperidone orodispersible tablets (Risperdal Quicklet⁰) (No. 41/03)

Janssen-Cilag Ltd Summary of Recommendation

9 May 2003

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

ADVICE

Recommended for restricted use within NHS Scotland

RECOMMENDATION

Risperdal Quicklet, for the treatment of acute and chronic schizophrenia and other similar psychotic conditions, should be reserved for those patients in whom rapid oral absorption is indicated.

Professor David H Lawson Chairman